EUVIMEDEUVIMED entdecken
Open Access

Supporting the Art: Medication Adherence Patterns in Persons Prescribed Ingestible Sensor-enabled Oral Pre-Exposure Prophylaxis to Prevent Human Immunodeficiency Virus Infection

Sara H Browne, Florin Vaida, Anya Umlauf, Amanda J Tucker, Terrence F Blaschke, Constance A Benson

Clinical Infectious Diseases · 2023

DOI: 10.1093/cid/ciac280 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Infectious Diseases, 2023. Verfasst von Sara H Browne und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases and Global Public Health, University of California San Diego, La Jolla, California, USA. Hauptthemen laut MEDLINE: Pre-Exposure Prophylaxis, Anti-HIV Agents, HIV Infections, Methamphetamine. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIMH NIH HHS, National Institutes of Health, National Institute of Mental Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Timely, accurate adherence data may support oral pre-exposure prophylaxis (PrEP) success and inform prophylaxis choice. We evaluated a Food and Drug Administration (FDA)-approved digital health feedback system (DHFS) with ingestible-sensor-enabled (IS) tenofovir-disoproxil-fumarate plus emtricitabine (Truvada®) in persons starting oral PrEP.

Methods

Human immunodeficiency virus (HIV)-negative adults were prescribed IS-Truvada® with DHFS for 12 weeks to observe medication taking behavior. Baseline demographics, urine toxicology, and self-report questionnaires were obtained. Positive detection accuracy and adverse events were computed as percentages, with Kaplan Meier Estimate for persistence-of-use. In participants persisting ≥28 days, adherence patterns (taking and timing) were analyzed, and mixed-effects logistic regression modeled characteristics associated with treatment adherence.

Results

Seventy-one participants were enrolled, mean age 37.6 years (range 18–69), 90.1% male, 77.5% White, 33.8% Hispanic, 95.8% housed, and 74.6% employed. Sixty-three participants (88.7%) persisted ≥28 days, generating 4987 observation days, average 79.2 (29–105). Total confirmed doses were 86.2% (95% confidence interval [CI] 82.5, 89.4), decreasing over time, odds ratio (OR) 0.899 (95% CI .876, .923) per week, P < .001; 79.4% (95% CI 66.7%, 87.3%) of participants had ≥80% adherence. Pattern analysis showed days without confirmed doses clustered (P = .003); regular dose timing was higher among participants with ≥80% confirmed doses (0.828, 95% CI .796 to .859) than among those with <80% (0.542, 95% CI95 .405 to .679) P < .001. In multi-predictor models, better adherence was associated with older age, OR 1.060 (95% CI 1.033, 1.091) per year, P < .001; negative vs positive methamphetamine screen, OR 5.051 (95% CI 2.252, 11.494), P < .001.

Conclusions

DHFS with IS-Truvada® distinguished adherent persons from those potentially at risk of prophylactic failure. Ongoing methamphetamine substance use may impact oral PrEP success.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pre-Exposure ProphylaxisAnti-HIV AgentsHIV InfectionsMethamphetamineAdultMaleHumansAdolescentYoung AdultMiddle AgedAgedFemaleEmtricitabine, Tenofovir Disoproxil Fumarate Drug CombinationEmtricitabineMedication AdherenceHomosexuality, Male

Stichwörter der Autor:innen

HIV prophylaxisadherenceingestible-sensorreal-time patterns

Substanzen

Emtricitabine, Tenofovir Disoproxil Fumarate Drug CombinationAnti-HIV AgentsEmtricitabineMethamphetamine

Autor:innen und Institutionen

  • Division of Infectious Diseases and Global Public Health, University of California San Diego, La Jolla, California, USA.
  • Specialists in Global Health, Encinitas, California, USA.
  • Department of Family Medicine and Public Health, University of California San Diego, La Jolla, California, USA.
  • Department of Psychiatry, University of California San Diego, La Jolla, California, USA.
  • Department of Medicine, Stanford University, Stanford, California, USA.

Förderung

  • NIMH NIH HHS
  • National Institutes of Health
  • National Institute of Mental Health

Zitieren

APA

Browne, S. H., Vaida, F., Umlauf, A., Tucker, A. J., Blaschke, T. F., & Benson, C. A. (2023). Supporting the Art: Medication Adherence Patterns in Persons Prescribed Ingestible Sensor-enabled Oral Pre-Exposure Prophylaxis to Prevent Human Immunodeficiency Virus Infection. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciac280

Vancouver

Browne SH, Vaida F, Umlauf A, Tucker AJ, Blaschke TF, Benson CA. Supporting the Art: Medication Adherence Patterns in Persons Prescribed Ingestible Sensor-enabled Oral Pre-Exposure Prophylaxis to Prevent Human Immunodeficiency Virus Infection. Clinical Infectious Diseases. 2023. doi:10.1093/cid/ciac280

BibTeX
@article{Browne2023,
  author = {Browne, Sara H and Vaida, Florin and Umlauf, Anya and Tucker, Amanda J and Blaschke, Terrence F and Benson, Constance A},
  title = {Supporting the Art: Medication Adherence Patterns in Persons Prescribed Ingestible Sensor-enabled Oral Pre-Exposure Prophylaxis to Prevent Human Immunodeficiency Virus Infection},
  journal = {Clinical Infectious Diseases},
  year = {2023},
  doi = {10.1093/cid/ciac280}
}
Kostenlos starten →